[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=53e2df694fb13a4d3e8cb46f85c784542c80f92f6aa417135a0b18f2310f0eee",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756485060,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136618026,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=53e2df694fb13a4d3e8cb46f85c784542c80f92f6aa417135a0b18f2310f0eee"
    }
  },
  {
    "ts": null,
    "headline": "ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?",
    "summary": "AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.",
    "url": "https://finnhub.io/api/news?id=5778f05411a82196571c26c33b1c12ac8249bff2e5939836b87b49deb3fee059",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756477020,
      "headline": "ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?",
      "id": 136573040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.",
      "url": "https://finnhub.io/api/news?id=5778f05411a82196571c26c33b1c12ac8249bff2e5939836b87b49deb3fee059"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=bb249aba37708c66fa706f4188b097de874e2596794778af5beaa46e65c2622d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756472406,
      "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
      "id": 136569135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=bb249aba37708c66fa706f4188b097de874e2596794778af5beaa46e65c2622d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
    "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
    "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756471054,
      "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
      "id": 136571810,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1823932204/image_1823932204.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
      "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada issues NOC to AbbVie’s upadacitinib for giant cell arteritis",
    "summary": "The authorisation is based upon results from the Phase III SELECT-GCA trial.",
    "url": "https://finnhub.io/api/news?id=1a39ce74327be313a31e6ff44b84eefe33b7d9d4ae9ca145ce136fe7b705ceb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756465399,
      "headline": "Health Canada issues NOC to AbbVie’s upadacitinib for giant cell arteritis",
      "id": 136569136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The authorisation is based upon results from the Phase III SELECT-GCA trial.",
      "url": "https://finnhub.io/api/news?id=1a39ce74327be313a31e6ff44b84eefe33b7d9d4ae9ca145ce136fe7b705ceb2"
    }
  },
  {
    "ts": null,
    "headline": "Assessing AbbVie’s Valuation After $1.2B Bretisilocin Acquisition Announcement",
    "summary": "Trying to decide whether to hold, sell, or even start a position in AbbVie right now? You are not alone. This stock has a way of capturing attention, with headlines swirling on new pipeline deals and price action that shifts just when you think you have it figured out. Over the past month, AbbVie's shares have jumped a strong 8.7%, and if you have been on board for five years, you are looking at an impressive return of 176.8%. Even over the past year, the stock has climbed 10.3%, easily...",
    "url": "https://finnhub.io/api/news?id=bf38e4b517ca497686981af5a9c850a6b9674d19cb23b6e6e8fa1098547307a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756462171,
      "headline": "Assessing AbbVie’s Valuation After $1.2B Bretisilocin Acquisition Announcement",
      "id": 136569137,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Trying to decide whether to hold, sell, or even start a position in AbbVie right now? You are not alone. This stock has a way of capturing attention, with headlines swirling on new pipeline deals and price action that shifts just when you think you have it figured out. Over the past month, AbbVie's shares have jumped a strong 8.7%, and if you have been on board for five years, you are looking at an impressive return of 176.8%. Even over the past year, the stock has climbed 10.3%, easily...",
      "url": "https://finnhub.io/api/news?id=bf38e4b517ca497686981af5a9c850a6b9674d19cb23b6e6e8fa1098547307a0"
    }
  },
  {
    "ts": null,
    "headline": "Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma",
    "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks. Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in antibody-based therapies for cancer and serious diseases, with notable successes including Darzalex (daratumumab) for multiple myeloma and epcoritamab for B-cell malignancies. Strategic partnerships with AbbVie and […]",
    "url": "https://finnhub.io/api/news?id=18b64cb23bd65c41a7e535bb5e783d419dd3b287701aca0739e25105a0446f37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756458757,
      "headline": "Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma",
      "id": 136569075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks. Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in antibody-based therapies for cancer and serious diseases, with notable successes including Darzalex (daratumumab) for multiple myeloma and epcoritamab for B-cell malignancies. Strategic partnerships with AbbVie and […]",
      "url": "https://finnhub.io/api/news?id=18b64cb23bd65c41a7e535bb5e783d419dd3b287701aca0739e25105a0446f37"
    }
  },
  {
    "ts": null,
    "headline": "Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally",
    "summary": "We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Genmab A/S is one of them. Genmab A/S (NASDAQ:GMAB), based in Copenhagen, is a biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. It is among the cheap biotech stocks to buy. With over 45 […]",
    "url": "https://finnhub.io/api/news?id=ad5bc7c564406b5477e1440941587d0745b47f2a1ca89ff84b7b97be5ce1a334",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756458138,
      "headline": "Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally",
      "id": 136569139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Genmab A/S is one of them. Genmab A/S (NASDAQ:GMAB), based in Copenhagen, is a biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. It is among the cheap biotech stocks to buy. With over 45 […]",
      "url": "https://finnhub.io/api/news?id=ad5bc7c564406b5477e1440941587d0745b47f2a1ca89ff84b7b97be5ce1a334"
    }
  },
  {
    "ts": null,
    "headline": "2 Reasons to Watch ABBV and 1 to Stay Cautious",
    "summary": "AbbVie currently trades at $207.60 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 9.2% gain during that period.",
    "url": "https://finnhub.io/api/news?id=7aab52c2104925d71b48e74163be45641a0a0f58c040db83f7c4f0addc3da604",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756440194,
      "headline": "2 Reasons to Watch ABBV and 1 to Stay Cautious",
      "id": 136569140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie currently trades at $207.60 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 9.2% gain during that period.",
      "url": "https://finnhub.io/api/news?id=7aab52c2104925d71b48e74163be45641a0a0f58c040db83f7c4f0addc3da604"
    }
  }
]